Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has terminated its license agreement with Daiichi Asubio Pharma regarding North American and European rights to carperitide for the treatment of acute heart failure.
Subscribe to our email newsletter
Astellas predecessor, Fujisawa Healthcare and Daiichi Asubio Pharma's predecessor, Daiichi Suntory Pharma executed the license agreement in May, 2003.
Astellas had conducted some clinical trials using carperitide in the US but after reassessing competitive circumstances and market potential, decided to discontinue carperitide development. As a result of this decision, both parties have agreed to terminate the license agreement. The drug was in the second of three stages of clinical studies needed for US approval.
Carperitide has been sold as Hanp in Japan to treat acute heart failure for more than a decade.